Anyone interested in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) should probably be aware that the President, Steven Hoerter, recently divested US$259k worth of shares in the company, at an average price of US$12.02 each. That sale was 35% of their holding, so it does make us raise an eyebrow.
See our latest analysis for Deciphera Pharmaceuticals
Deciphera Pharmaceuticals Insider Transactions Over The Last Year
Notably, that recent sale by Steven Hoerter is the biggest insider sale of Deciphera Pharmaceuticals shares that we've seen in the last year. That means that an insider was selling shares at around the current price of US$11.86. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.
In the last twelve months insiders purchased 21.00k shares for US$291k. But they sold 55.89k shares for US$806k. All up, insiders sold more shares in Deciphera Pharmaceuticals than they bought, over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
I will like Deciphera Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
Insider Ownership
Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 0.6% of Deciphera Pharmaceuticals shares, worth about US$5.8m, according to our data. We do generally prefer see higher levels of insider ownership.
So What Do The Deciphera Pharmaceuticals Insider Transactions Indicate?
Insiders sold Deciphera Pharmaceuticals shares recently, but they didn't buy any. Despite some insider buying, the longer term picture doesn't make us feel much more positive. When you consider that most companies have higher levels of insider ownership, we're a little wary. So we're not rushing to buy, to say the least. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To assist with this, we've discovered 3 warning signs that you should run your eye over to get a better picture of Deciphera Pharmaceuticals.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.